Sildenafil improves erectile function by inhibiting the cGMP-catalytic activity of phosphodiesterase type V (PDE5). We used rapid amplification of cDNA Ends-polymerase chain reaction (RACE-PCR) to isolate three PDE5 isoforms from human corpus cavernosum. Semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis on eight human cavernous tissue samples showed that all samples expressed the PDE5A1 at a lower level than the PDE5A2 isoform. Five samples expressed the PDE5A3 isoform at various levels while the other three did not. Analysis on non-penile tissues showed that all tissues expressed the A1 and A2 isoforms while only those that have substantial amounts of smooth muscle expressed the A3 isoform. Cloning and sequencing of the PDE5A gene showed that the isoform-specific 5 0 -ends of the PDE5 mRNAs are encoded from three alternative first exons arranged in the order of A1 -A3 -A2. Promoter activities were detected upstream from the A1-specific exon and in the intron preceding the A2-specific exon. The upstream PDE5A promoter is expected to direct the expression of all three PDE5 isoforms while the intronic PDE5A2 promoter only the A2 isoform. Both promoters were upregulated by increasing concentrations of either cAMP or cGMP. Several transcription factor AP2 and Sp1-binding sequences identified in the promoters are likely to be the mediators of cAMP=cGMP-responsiveness.
Introduction
Cyclic AMP (cAMP) and cyclic GMP (cGMP) are intracellular messengers that mediate the effects of extracellular signaling molecules (for example, neurotransmitters and hormones) by interacting with intracellular targets such as protein kinases, ion channels and transcription factors. Their intracellular concentrations are critical for a variety of cellular functions and are balanced between their synthesis and destruction that are carried out by cyclases and phosphodiesterases (PDEs), respectively. By targeting specific PDEs, numerous pharmaceutical compounds have been developed during the past decades to regulate cellular cAMP and cGMP concentrations as a means to treat ailments such as asthma and heart failure. 1, 2 Phosphodiesterase type 5 (PDE5) is a cGMPbinding, cGMP-specific hydrolytic enzyme that has been the subject of many recent clinical and basicscience studies because it was shown to be the target of sildenafil, the active ingredient of the widely prescribed impotence drug Viagra. 3, 4 For patients with erectile dysfunction, the inhibitory effect of sildenafil on PDE5 allows the accumulation of cGMP in the corpus cavernous smooth muscle cells (CSMC). The resulting elevated cGMP concentration enables the relaxation of CSMC and hence erection of the penis. 5 PDE5 was first purified from rat lung, 6 and its enzyme activity has subsequently been identified in many other tissues. Proteolytic digestion of PDE5 produces a C-terminal fragment and an N-terminal fragment that exhibit cGMP-catalytic and cGMPbinding activities, respectively. 7 Molecular cloning of PDE5 was first accomplished with the isolation of a bovine PDE5 cDNA. 8 A rat PDE5 cDNA with a very different 5 0 end was subsequently isolated. 9 The human equivalent of the bovine PDE5 cDNA was published by three independent groups. 10 -12 The human equivalent of the rat PDE5 cDNA has also been presented. 11 Based on standard nomenclature for PDE gene families, the bovine PDE5 cDNA and its human equivalent are now classified as to encode the PDE5A1 isoform, and the rat PDE5 cDNA and its human equivalent the PDE5A2. We have recently isolated a third PDE5 isoform, PDE5A3. 13 These three isoforms differ only in the N-terminal sequence and are presumably generated through alternative splicing of the first exon of the PDE5A gene.
The human PDE5A gene has been mapped to chromosome 4q26 and has been reported to contain 21 exons that span approximately 100 kilobases. 11, 12 We have now identified two additional exons that represent two of the three alternative first exons. 14 We report here functional analysis of the flanking region upstream from the 5 0 -most first exon and the regions preceding the other two alternative first exons. We will present evidence for the existence of two alternate gene promoters, one is capable of transcribing all three PDE5 isoforms, while the other is specific for the PDE5A2 isoform.
Materials and methods

Cell culture
Monkey fibroblast cell line COS-7 was purchased from American Type Culture Collection (Manassas, VA, USA) and grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum.
RNA preparation
Human tissues were obtained from patients undergoing penile prosthesis implantation. All procedures regarding the collection and use of human tissues were approved by the UCSF Committee on Human Research. The surgically removed tissues were homogenized in Tri-Reagent RNA extraction solution (Molecular Research Center, Cincinnati, OH, USA). Following the recommended procedure by the supplier, RNAs were extracted and further treated with DNase I to remove traces of contaminating DNA. Quantity and integrity of RNAs were examined by spectrophotometry and agarose gel electrophoresis, respectively. Human skeletal muscle, heart, brain, kidney and liver RNAs were purchased from Clontech Laboratories, Inc. (Palo Alto, CA, USA).
Oligonucleotide primers
Oligonucleotides used in reverse transcriptionpolymerase chain reaction (RT-PCR) analyses and rapid amplification of CDNA Ends-polymerase chain reaction (RACE-PCR) cloning are listed in Table 1 .
RT-PCR analysis
RT-PCR was performed in an RT step and a PCR step. In the RT step, the mRNAs were reversetranscribed into a 'library' of complementary DNAs (cDNAs). This cDNA library was then used for the analysis of various genes in the PCR step. The RT procedure was performed with the SuperScript reverse transcriptase (Life Technologies, Inc., Gaithersburg, MD, USA) and its accompanying reagents. Briefly, 2.5 mg of each tissue RNA was annealed to 0.4 mg of oligo-dT primer in a volume of 12 ml. Four microlitres of 56 buffer, 2 ml of 0.1 M DTT, 1 ml of 10 mM dNTP, and 1 ml of SuperScript reverse transcriptase were then added to bring the final reaction volume to 20 ml. After 1 h of incubation at 42 C, the RT mixture was incubated at 70 C for 10 min to inactivate the reverse transcriptase. Eighty microlitres of TE buffer was then added to make a 56 diluted library. A portion of this library was further diluted to various concentrations (up to 1006dilution). One microlitre of each dilution was then used in a 10-ml PCR to identify the optimal input within the linear amplification range. In addition to the 1-ml diluted library, the PCR mixture consisted of 10 ng of each of a primer pair and reagents supplied with the Taq polymerase (Life Technologies, Inc., Gaithersburg, MD, USA 17 and sequenced.
Isolation of PDE5A gene fragments
Genomic DNAs were prepared from PDE5A genecontaining yeast clones 851A5 and 851B10 (Research Genetics, Inc. Huntsville, AL, USA), digested with HindIII, NotI, BspHI, and=or XhoI restriction enzymes, ligated to pMECA 17 or pBluescript (Stratagene, Inc., La Jolla, CA, USA) plasmid, and transformed into E. coli strain DH5a (Life Technologies, Inc., Gaithersburg, MD, USA). The transformed bacteria were screened by hybridization with a 32 P-labeled PDE5A3 isoform-specific cDNA probe and by selection for known restriction sites (GeneBank accession number AB00161S01). Positive clones were confirmed by DNA sequencing.
Construction of luciferase reporter plasmids
The luciferase reporter system of Promega Inc. (Madison, WI, USA) was used for the identification of PDE5 gene fragments with promoter activities. In this system the enhancer-less pGL3-basic plasmid and the SV40 enhancer-containing pGL3-enhancer plasmid were designed for the cloning of DNA fragments that contain potential promoters. DNA fragments covering various regions of the potential gene promoters were prepared by restriction digestion or by PCR and cloned into pGL3 plasmids.
Analysis of promoter activities
COS-7 cells were transiently transfected by lipofection using the Superfectin kit (Qiagene, Valencia, CA, USA). To normalize the data for transfection efficiency, the pRL-SV40 plasmid (Promega Inc. Madison, WI, USA), which contains the Renilla luciferase reporter cDNA under the transcriptional control of the SV40 promoter, was co-transfected with each test plasmid (pGL3-basic and its PDE5A gene-containing derivatives). The cells to be transfected were seeded at approximately 2610 5 per well in a 6-well plate. The next day, 2 mg of each test plasmid DNA and, when indicated, 0.5 ng of pRL-SV40 were transfected into the cultured cells in each well. Twenty-four hours later, the cells were treated with 0 -5 mM of db-cAMP or db-cGMP. The cells were further maintained for 48 h before being washed and lysed in 100 ml of lysis buffer (Promega Inc. Madison, WI, USA). The activities of firefly luciferase (test plasmid) and Renilla luciferase (control plasmid) were measured in 20-ml aliquots of each cell lysate using the Dual-Luciferase reporter assay system (Promega Inc. Madison, WI, USA) and the TD-20=20 luminometer (Turner Designs Inc., Sunnyvale, CA, USA). Each test plasmid was transfected and assayed for luciferase activity at least three times. It should be noted that in pilot experiments co-transfection with pRL-SV40 had no effect on the luciferase activities of any of the tested plasmids.
DNase I footprint analysis
To identify interactions between transcription factors and PDE5A1 promoter, DNase I footprint analysis 18 was employed. DNA fragments containing the promoters were prepared by restriction enzyme digestion and labeled with g-32 P-ATP at the 5 0 ends. Each fragment was then cut with an appropriate restriction enzyme to remove one of the labeled ends. Approximately 1 ng of the single-endlabeled probe was mixed with 10 ng of transcription factor AP1, AP2, Sp1 (Promega Inc.), or Ets, 15 0.5 mg of poly (dI-dC) and 2% of polyvinyl alcohol in a reaction volume of 10 ml. After incubation at room temperature for 15 min, 1 ml (0.01 unit) of DNase I was added to the probe=protein mixture and incubated at room temperature for 1 min. The reaction was stopped by the addition of 25 ml of stop solution (0.2 M NaCl, 20 mM EDTA, 1% NaDodSO 4 , 0.2 mg=ml tRNA), followed by phenol= chloroform extraction and ethanol precipitation. The reaction products were then electrophoresed in a 6% polyacrylamide -7 M urea sequencing gel along with a sequencing ladder produced by chemical cleavage at the A and G nucleotides of the probe. 19 PDE5A gene encodes three isoforms from two promoters C-S Lin et al
Results
Cloning of three PDE5A isoforms from human penis
Based on the belief that the cloned bovine 8 and rat 9 PDE5 cDNAs represent two distinct isoforms, we sought to isolate possible PDE5 isoforms from human penis by the RACE-PCR technique, which is capable of isolating cDNA ends of unknown sequences. Using the procedure described in Materials and methods, we isolated a total of 16 PDE5A 5 0 -end cDNA clones. Two of these clones corresponded to the bovine PDE5A cDNA (PDE5A1, Figure 1 ) and five other clones corresponded to the rat PDE5A cDNA (PDE5A2, Figure 1 ). The remaining nine clones did not match either the bovine or the rat PDE5A cDNAs and therefore were novel PDE5A cDNAs (PDE5A3, Figure 1) . Examination of the isoform-specific region of the novel PDE5A3 clones failed to identify an in-frame ATG that could serve as the translation initiation codon. It therefore appears that the translation initiation codon of PDE5A3 could be an in-frame ATG located downstream from the divergent point. The sequences surrounding this ATG are in conformity with the Kozak criteria for translation initiation. 20 Because this ATG corresponds to the second in-frame ATG in PDE5A1 and PDE5A2, the predicted PDE5A3 protein would be an Nterminally truncated form of PDE5A1 and PDE5A2.
Expression of PDE5A isoforms in human penile tissue samples
Based on the nucleotide sequences of the above newly isolated human PDE5A cDNAs, we were able to design and synthesize isoform-specific primers (PDE5As, PDE5Bs and PDE5Cs, Table 1 ) for semiquantitative RT-PCR analysis. In the experiment, each of the three isoform-specific primers was used as the upstream primer, while another primer, PDE797a (Table 1) , whose sequence was derived from the common region, was used as the downstream primer. We analyzed PDE5 isoform expression in a panel of eight human penile tissue samples (all obtained from patients undergoing prosthesis implantation). The results (Figure 2) showed that PDE5A2 was abundantly expressed in all eight samples, PDE5A1 was also expressed in all samples albeit at much reduced levels, and PDE5A3 was expressed in five of the eight samples with varied levels of abundance. The three PDE5A3-negative samples were collected from patients undergoing second prosthesis implantation. These patients' corpus cavernosum had marked fibrosis due to the first prosthesis implantation. Their diminished Figure 1 Nucleotide sequences of the isoform-specific regions of PDE5A cDNAs. The complete sequences of the three isoforms were identical except for the sequences upstream from the methionine residue marked with an asterisk (M*). Arrows indicate junctions between first and second exons. Underlined sequences are NsiI restriction sites that were used for cloning the 5 0 ends of PDE5A isoforms. GeneBank accession numbers of these three sequences are AF155192, AF155193 and AF155194, respectively.
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muscle content may correlate with lack of PDE5A3 expression (see below).
Expression of PDE5A isoforms in non-penile human tissues
To identify the expression patterns of PDE5A isoforms in non-penile human tissues, we performed RT-PCR analysis on RNA samples that were either purchased or isolated from surgically removed tissues. The results (Figure 3) showed that both A1 and A2 isoforms were abundantly expressed in most tissues, whereas A3 was expressed at various levels ranging from high to not detectable. The tissues that did not have a detectable level of A3 expression were brain, liver, lung, kidney and leg muscle, all of which lack a smooth or cardiac muscle component. On the other hand, all of the tissues that had some degree of A3 expression (including prostate, heart, urethra, uterus and bladder) have a Figure 2 Expression of PDE5A isoforms in human corpus cavernosum. RNAs of eight patients' corpus cavernosum were subjected to RT-PCR (see Materials and methods) with primer pair PDE5A-s (specific for PDE5A1) and PDE-797a, primer pair PDE5B-s (specific for PDE5A2) and PDE797a, primer pair PDE5C-s (specific for PDE5A3) and PDE797a, and primer pair bactin-s and b-actin-a ( Table 1 ). The reaction products were electrophoresed in a 1.5% agarose gel and stained with ethidium bromide. The RT-PCR product in each lane was derived from 25 ng (for PDE5A1, A2 and A3) or 1 ng (for b-actin) of total tissue RNAs. M, 100-bp size marker. 15) were subjected to RT-PCR with primer pair PDE5A-s (specific for PDE5A1) and PDE-797a, primer pair PDE5B-s (specific for PDE5A2) and PDE797a, primer pair PDE5C-s (specific for PDE5A3) and PDE797a, and primer pair b-actin-s and b-actin-a ( Table 1 ). The reaction products were electrophoresed in a 1.5% agarose gel and stained with ethidium bromide. The RT-PCR product in each lane was derived from 25 ng (for PDE5A1, A2 and A3) or 1 ng (for b-actin) of total tissue RNAs. M, 100-bp size marker. Lane 1, benign prostate hypertrophy; Lane 2, urinary bladder 1; Lane 3, urinary bladder 2; Lane 4, urinary bladder tumor; Lane 5, urethra 1; Lane 6, urethra 2; Lane 7, urethra 3; Lane 8, uterus; Lane 9, heart; Lane 10, leg muscle; Lane 11, lung; Lane 12, lung tumor; Lane 13, brain; Lane 14, kidney; Lane 15, liver.
PDE5A gene encodes three isoforms from two promoters C-S Lin et al smooth or cardiac muscle component. It is therefore likely that the A3 isoform is specific for smooth and=or cardiac muscles.
Isolation of genomic sequences encompassing three alternative first exons
Having identified three distinct PDE5 isoforms, we then sought to map them to the human genome. We took advantage of a report that three commercially available yeast clones contain the human PDE5A gene. 11 We used their DNAs for the construction of 'mini' genomic libraries to facilitate the isolation of PDE5A gene fragments. We isolated three DNA fragments that, when assembled together, were 5.8 kb in length and covered the 5 0 flanking region and all three alternative first exons of the PDE5A gene ( Figure 4 ). We obtained a continuous nucleotide sequence of 5.5 kb (GeneBank accession numbers AF319172 and AF155195) and identified three alternative first exons that are arranged in the order of A1 -A3 -A2 (Figure 4 ). These three exons are separated by two introns of 434 bp and 361 bp, respectively.
Localization of promoters
Although PDE5A isoforms were presumed to be generated by alternative splicing of a common mRNA, it remains possible that they could be derived from three separate mRNAs that are transcribed from three distinct gene promoters. To locate potential promoters, we systematically analyzed several DNA fragments that represent various regions upstream from each of the three alternative first exons (Figures 5 and 6 ). These DNA fragments were cloned into luciferase reporter plasmids and tested for their ability to 'promote' the expression of the luciferase gene. We identified a relatively strong promoter adjacent to the PDE5A1-specific first exon and a weaker promoter near the PDE5A2-specific first exon (Figures 4 and 7) . No promoter activities were associated with the entire intronic region upstream from the PDE5A3-specific first exon ( Figure 6 ). The basal promoter for the PDE5A gene was only 139 bp in length (fragment OM, Figure 5 ) and included 78 bp of exon sequence. This basal promoter required additional sequences upstream and downstream in order to exert inducible promoter activities (see below). In contrast, the PDE5A2 promoter had both the basal and inducible promoter activities located in a 182-bp genomic fragment (see below).
Regulation by cAMP and cGMP
Because cGMP is the substrate for PDE5, it is possible that high concentrations of cGMP may stimulate PDE5 production by upregulating the PDE5A gene promoters. We tested this possibility with two PDE5A promoter-containing fragments, EX and NX ( Figure 5 ) and with two PDE5A2 promotercontaining fragments, A2-2 and A2-2D ( Figure 6 ). The results showed that all four DNA fragments had increasing promoter activities when their transfected cells were treated with increasing concentrations of cGMP ( Figure 7 ). Further testing of various DNA fragments ( Figure 5 ) with 2 mM of cGMP showed that the cGMP-responsive sequences were located in a 308-bp region (between the NheI and NotI sites, Figure 5 ) and a 156-bp region (between the XmaI and XhoI sites, Figure 5 ). These two regions are located upstream and downstream, respectively, from the 139-bp basal PDE5A promoter (fragment OM, Figure 5 ). In contrast, the cGMPresponsive regions in the PDE5A2 promoter are located in the same DNA fragments as the basal promoter (Figures 6 and 7) . Several Sp1 and AP2 transcription factor binding sequences are located in the cGMP-responsive regions of the PDE5A promoter and in the PDE5A2 promoter ( Figure 7) . Because Sp1-and AP2-binding sequences are known to confer cAMP-responsiveness to many mammalian genes, we also tested the PDE5A and PDE5A2 promoters for responsiveness to cAMP. We conducted similar experiments as above except that cGMP was replaced with cAMP. 
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We obtained results that were very similar to those obtained with cGMP.
Discussion
Since its debut in 1998, the impotence drug Viagra has attracted much attention from both clinicians and basic-research scientists. Several pharmaceutical companies are also engaged in the development of next-generation sildenafil-like drugs that may have better efficacy and lesser side effects. These interests and efforts inevitably require a better understanding of the target of sildenafil, PDE5, and the PDE5A gene.
To this end, we have identified three PDE5 isoforms from human penile tissues and located the promoter sequences of the human PDE5A gene. 
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The three PDE5 isoforms differ only in the Nterminal, in which no biochemical or physiological function has been identified. Of particular interest is the PDE5A1 isoform that has 13 glutamine residues in a stretch of 18 amino acids near the N-terminal. Polyglutamine sequences have been shown to act like zippers that mediate protein -protein interactions. 21 Polymorphism in the polyglutamine region of the androgen receptor has been associated with prostate, 22 uterine 23 and breast cancers, 24 with rheumatoid arthritis, 25 and with male infertility. 26 Expansion of the polyglutamine region in other proteins has also been linked to several neurological disorders, including Huntington's disease. 27 However, whether the polyglutamine region in PDE5A1 has a function remains to be seen. Other possible functional differences between the PDE5 isoforms may include their subcellular localization, enzymatic activity, and sensitivity to inhibitors, as is the case with the isoforms of the human PDE4D gene. 28 We demonstrated that the PDE5 isoform-specific sequences were encoded from three alternative first exons of the PDE5A gene. The three alternative first exons are arranged in the order of A1 -A3 -A2 and are separated by an intron of 434 bp between A1 and A3 and by another intron of 361 bp between A3 and A2 ( Figure 4) . We further demonstrated that the intron preceding the A2-specific exon possessed promoter activities that would allow the expression of the PDE5A2 isoform independent of the other two isoforms. This PDE5A2 promoter was only 182 bp in size (A2 -2D fragment, Figure 6 ) and contained an Sp1-binding sequence that was critical for both the basal and cGMP=cAMP-inducible promoter activities.
While the PDE5A2 promoter can only control the expression of PDE5A2 isoform, the PDE5A promoter should direct the expression of all three isoforms. This bona fide PDE5A promoter is structurally unusual in that it is not only very small but also has substantial representation from the first exon sequence. Full basal promoter activity required only 139 bp, of which 78 bp belong to the first exon. A lesser promoter activity was still detectable with a 94-bp fragment (fragment SM, Figure 5 ) that contains the same 78-bp exon sequence. This basal promoter has no AP2 or Sp1-binding sequences and responded to cGMP or cAMP stimulation poorly. On the other hand, a 308-bp upstream extension or a 156-bp downstream extension provided cGMP= cAMP responsiveness to the PDE5A promoter. The cGMP=cAMP responsiveness is most likely mediated by Sp1 and=or AP2 sequences that exist in multiple copies in the two extensions.
The ability of cGMP to upregulate both the PDE5A and PDE5A2 promoters implies that medicines (such as, sildenafil) that raise a patient's intracellular cGMP concentration may have the PDE5A gene encodes three isoforms from two promoters C-S Lin et al unintended side effect of activating the PDE5A gene. This possibility may perhaps explain why some impotent patients require ever-larger prescriptions of Viagra, as we have observed in our clinic at UCSF.
To test this possibility, we plan to use animal and cell culture models that will be fed with various cGMP-elevating compounds. If our hypothesis is correct, we should see increased synthesis of PDE5 mRNA and proteins. Although the induction of PDE5A promoters by cGMP was anticipated, their induction by cAMP was not, because the increased PDE5A promoter activity can only lead to increased hydrolysis of cGMP but not cAMP. However, there is increasing evidence that cAMP and cGMP share many common elements in their overlapping signal-transduction pathways. For example, we have recently shown that cAMP was equally effective as cGMP in activating protein kinase G, 29 which has long been considered a specific target of cGMP. As such, we speculate that the ability of cAMP to upregulate PDE5A promoters was due to its overlapping signaltransduction pathways with cGMP. Despite that the increased synthesis of PDE5 would have little effect on the breakdown of cAMP, there is a distinct possibility that the increased level of cAMP could also upregulate certain cAMP-specific phosphodiesterases (ie PDE4, PDE7 and PDE8) that can then digest the excessive cAMP. 30 In this scenario, the increased level of cAMP not only accelerates the breakdown cAMP but also cGMP.
